Gilead Sciences
GILD
1,644 hedge funds and large institutions have $75B invested in Gilead Sciences in 2020 Q1 according to their latest regulatory filings, with 257 funds opening new positions, 635 increasing their positions, 623 reducing their positions, and 148 closing their positions.
141% more funds holding in top 10
Funds holding in top 10: 37 → 89 (+52)
74% more first-time investments, than exits
New positions opened: 257 | Existing positions closed: 148
22% more call options, than puts
Call options by funds: $2.4B | Put options by funds: $1.96B
13% more capital invested
Capital invested by funds: $66.2B → $75B (+$8.8B)
6% more funds holding
Funds holding: 1,556 → 1,644 (+88)
2% more repeat investments, than reductions
Existing positions increased: 635 | Existing positions reduced: 623
0.55% less ownership
Funds ownership: 80.53% → 79.98% (-0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$3B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$1.77B |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$750M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$328M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$286M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sanders Capital
West Palm Beach,
Florida
|
-$740M |
| 2 |
Bank of New York Mellon
New York
|
-$701M |
| 3 |
Parnassus Investments
San Francisco,
California
|
-$457M |
| 4 |
BlackRock
New York
|
-$363M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$325M |
GILD Hedge Fund Activity: Q1 2020 in Review
1,644 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2020, worth a combined $75B — up 13% from $66.2B a quarter earlier.
Buyers outnumbered sellers: 257 funds opened new GILD positions and 148 closed out — a net gain of 109 holders — while 635 added to existing stakes and 623 trimmed.
The largest buyer was Capital International Investors, adding an estimated $3B. The largest seller was Sanders Capital, exiting entirely with an estimated $740M sold.
- 1,644 institutional investors held Gilead Sciences (GILD) as of Q1 2020, up from 1,556 in Q4 2019.
- Funds reported $75B of Gilead Sciences stock for Q1 2020, up 13% quarter-over-quarter.
- 257 funds opened new Gilead Sciences positions in Q1 2020 and 148 closed out, a net change of +109 holders.
- The largest Gilead Sciences buyer in Q1 2020 was Capital International Investors, an estimated $3B added.
- The largest Gilead Sciences seller in Q1 2020 was Sanders Capital, an estimated $740M sold.
Based on aggregated 13F filings for Q1 2020.